For now, the approval highlights a growing role for liquid biopsy, ctDNA testing, and precision medicine in cancer treatment. Instead of relying solely on scans to determine whether breast cancer is responding to therapy, doctors may increasingly use molecular changes in the bloodstream to identify treatment resistance earlier.
